Industry Insights

• 
  Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified? Krebs Qin
  March 14, 2025
  The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
• 
  Top 10 Sales Volume of New Drugs of Traditional Chinese Medicine: Behind the Numbers - Only 2 Out of 29 Surpassed RMB 100 Million in Sales Xiao Yan
  March 14, 2025
  From 2016 - 2024, TCM new drugs made progress but lagged in sales. This article analyzes reasons and explores future directions.
• 
  A Decade of Transformation in China's Innovative Drug Industry: The Journey from Follower to Leader Kevin
  March 14, 2025
  Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro

• 
  Global Shingles (Herpes Zoster) Market Trends and Prospects David Orchard-Webb
  March 18, 2025
  The global shingles market is growing due to factors like an aging population. It elaborates on drivers, segmentation, competition, and future trends.

• 
  InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China PharmaSources
  March 20, 2025
• 
  Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD PharmaSources
  March 11, 2025
• 
  InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
  February 18, 2025
  InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.

• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
  Mugwort, also known as fragrant mugwort or Artemisia argyi, is a herbaceous plant belonging to the Compositae family.
• 
  Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
  July 19, 2024
• 
  Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives Xiaomichong
  July 19, 2024

• 
  20 Years of Growth and Innovation in China, Fette Compacting Launches F30p Tablet Press PharmaSources
  December 13, 2024
  Interview Dr. Andreas Risch——Managing Director of Fette Compacting (China) Co., Ltd.